doi: 10.1136/bmj.38582.703866.AE.
Epub 2005 Sep 2.
"Breakthrough" drugs and growth in expenditure on prescription drugs in Canada
Affiliations
- PMID: 16141448
- PMCID: PMC1246080
- DOI: 10.1136/bmj.38582.703866.AE
Item in Clipboard
"Breakthrough" drugs and growth in expenditure on prescription drugs in Canada
BMJ.
.
No abstract available
Figures
Use of prescription drugs and expenditure per capita, by product classification, British Columbia, Canada, 1996-2003. Data were extracted from BC PharmaNet, a computer network into which a record of all filled prescriptions (including the data field for days of treatment supplied) must be entered by law
Similar articles
-
Trends and determinants of prescription drug expenditures in the elderly: data from the British Columbia Pharmacare Program.Inquiry. 1993 Summer;30(2):199-207. Inquiry. 1993. PMID: 8314608
-
Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia.Health Policy. 2004 Jun;68(3):299-307. doi: 10.1016/j.healthpol.2003.10.006. Health Policy. 2004. PMID: 15113641
-
Prescription drugs and the changing concentration of health care expenditures.Health Aff (Millwood). 2007 Jan-Feb;26(1):249-57. doi: 10.1377/hlthaff.26.1.249. Health Aff (Millwood). 2007. PMID: 17211035
-
The economics of prescription drug prices, government intervention, and the importation of drugs from Canada.Nurs Econ. 2005 Nov-Dec;23(6):307-11, 279. Nurs Econ. 2005. PMID: 16459902 Review.
-
Trends in retail prescription expenditures.Health Aff (Millwood). 1990 Fall;9(3):131-45. doi: 10.1377/hlthaff.9.3.131. Health Aff (Millwood). 1990. PMID: 2121634 Review. No abstract available.
Cited by
-
Drugs Becoming Generics-The Impact of Genericization on the Market Performance of Antihypertensive Active Pharmaceutical Ingredients.Int J Environ Res Public Health. 2021 Sep 7;18(18):9429. doi: 10.3390/ijerph18189429. Int J Environ Res Public Health. 2021. PMID: 34574353 Free PMC article.
-
Few new drugs deserve expedited regulatory treatment.J Manag Care Spec Pharm. 2021 May;27(5):685-688. doi: 10.18553/jmcp.2021.27.5.685. J Manag Care Spec Pharm. 2021. PMID: 33908278 Free PMC article.
-
We need to mandate drug cost transparency on electronic medical records.CMAJ. 2017 Dec 18;189(50):E1541-E1542. doi: 10.1503/cmaj.171070. CMAJ. 2017. PMID: 29255097 Free PMC article. No abstract available.
-
We need a "made in Canada" orphan drug framework.CMAJ. 2017 Oct 16;189(41):E1274-E1275. doi: 10.1503/cmaj.170195. CMAJ. 2017. PMID: 29038319 Free PMC article. No abstract available.
-
How important is mode of administration in treatments for rheumatic diseases and related conditions?Curr Rheumatol Rep. 2015 Jun;17(6):514. doi: 10.1007/s11926-015-0514-3. Curr Rheumatol Rep. 2015. PMID: 25903666 Review.
References
-
- Canadian Institute for Health Information. Drug expenditures in Canada 1985-2004. Ottawa: CIHI, 2005.
-
- Patented Medicine Prices Review Board. Annual report 2003. Ottawa: PMPRB, 2004: 49.
-
- World Health Organization. Guidelines for ATC classification and DDD assignment 2004. 7th ed. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 2004.
-
- Davis P. “Tough but fair”? The active management of the New Zealand drug benefits scheme by an independent Crown agency. Aust Health Rev 2004;28: 171-81. - PubMed
-
- IMS. Global pharmaceutical sales by region, 1997-2004. IMS Health, 2005.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
